Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-04-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事对公司对外担保情况及关联方占用资金情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees and related party fund occupation, referencing regulatory notices from the China Securities Regulatory Commission. It details specific guarantee amounts, approvals from shareholders' meetings, and confirms no irregularities in fund occupation. The document is a regulatory compliance statement rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis but serves as an independent opinion on specific regulatory matters. Given its nature and length (1287 characters), it fits best as a Regulatory Filings (RNS) document, which is a fallback category for compliance and regulatory announcements that do not fit other categories.
2018-04-25 Chinese
2017年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2017 年度内部控制评价报告' which translates to '2017 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2017, including financial and non-financial internal control defects, their identification, and remediation. The document includes detailed internal control standards, scope, and conclusions about the effectiveness of internal controls. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. The document length is 4684 characters, which is sufficient to be a full report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2017
2018-04-25 Chinese
2017年度社会责任报告
Environmental & Social Information Classification · 100% confidence The document is titled '2017 年度社会责任报告' which translates to '2017 Annual Social Responsibility Report'. It is a detailed report covering the company's efforts and contributions in economic, social, and environmental aspects during the 2017 fiscal year. The content includes sections on company overview, governance, market responsibility, social responsibility, environmental responsibility, and future outlook. It is explicitly described as a social responsibility report, which aligns with Environmental & Social Information filings. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is an annual financial report, audit report, or any other category. Therefore, the appropriate classification is Environmental & Social Information (SR).
2018-04-25 Chinese
董事会审计委员会2017年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2017年度履职情况报告" (2017 Annual Performance Report) of the Board Audit Committee of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the activities, meetings, and evaluations conducted by the audit committee during 2017, including oversight of the external auditor, review of the 2016 financial audit, internal control assessments, and coordination with management and auditors. The document is a report on the audit committee's duties and performance rather than the audit report itself or the full annual report. It is a standalone report focusing on audit committee activities and oversight, which aligns with the definition of an Audit Report / Information (AR). The document length is about 2054 characters, which is relatively short but contains substantive content about audit committee work, not merely an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2017
2018-04-25 Chinese
关于控股股东部分股权解除质押及再质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and the purpose of the pledge, including risk disclosures. There is no financial statement, audit, or management discussion. The document is a regulatory announcement about share pledging activities, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share pledging status, a capital structure matter. The document length is short and it is not a report or a certification, so it is not RPA or RNS. Therefore, the best classification is SHA.
2018-04-23 Chinese
关于收到美国外国投资委员会（CFIUS）通知函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company regarding receipt of a notification from the U.S. Committee on Foreign Investment (CFIUS) about the review and clearance of a major asset restructuring transaction involving the indirect acquisition of OriGene Technologies, Inc. It mentions prior board resolutions and disclosures related to the transaction and notes the uncertainty of approval from the China Securities Regulatory Commission. The document is short (692 characters) and serves as a regulatory update on the status of a transaction, not a full report or detailed financial disclosure. It does not contain financial statements or detailed analysis but is an official regulatory announcement about a transaction review and approval status. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-04-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.